Australia & United States — Food and Drug Administration
30 shared events · Importance 8 · Last updated Aug 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
Australia: Relfydess (RelabotulinumtoxinA) is already approved and launched in Australia, indicating that the regulatory issues in the United States do not affect its status in this region.
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Galderma Group for RelabotulinumtoxinA, citing observations during a manufacturing site inspection and analytical method optimization, which delays the product's approval in the United States.
Jul 01, 2026 · 6 articles
Business
Australia: Australia serves as a new commercial market for Idefirix, with the TGA approval enabling access for highly sensitized kidney transplant patients. The country's registry will generate real-world evidence.
United States — Food and Drug Administration: The FDA's acceptance of the BLA and PDUFA date of December 19, 2026, are key upcoming regulatory milestones for GT Biopharma in the US market.
Aug 18, 2026 · 6 articles
Regulatory
Australia: Australia is reviewing the vaccine, potentially broadening its availability.
United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.
Aug 05, 2026 · 105 articles
Business
Australia: Australia is the home country of Navi and Australia — Innovation Victoria, benefiting from the success of its medtech sector.
United States — Food and Drug Administration: The FDA granted 510(k) clearance in 2025 and an expanded indication in 2026, enabling Navi to enter the US market.
Jul 29, 2026 · 6 articles
Tech
Australia: Australian researchers and The Australia Institute are involved in the trial.
United States — Food and Drug Administration: The FDA will review the trial data for potential approval. The companies plan to file for approval, and the vaccine could be available as soon as 2027 if approved.
Aug 19, 2026 · 108 articles
International
Australia: The Australian market is trading sharply lower, influenced by global negative cues and concerns about the Middle East conflict's impact on commodity prices and overall economic stability.
United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.
May 18, 2026 · 316 articles
Tech
Australia: Already authorized psilocybin for treatment-resistant depression; this trial may reinforce its regulatory stance.
United States — Food and Drug Administration: Regulatory body that may use these results to inform decisions on psychedelic therapies, potentially accelerating approvals.
Jul 30, 2026 · 6 articles
Business
Australia: Imlifidase is approved in Australia, demonstrating its global market presence beyond Europe.
United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the Biologics License Application for imlifidase in February 2026, indicating potential future market expansion for the drug in the US.
May 27, 2026 · 6 articles
Business
Australia: Australia is one of the international markets where CannEpil has been made available.
United States — Food and Drug Administration: United States — Food and Drug Administration has engaged with the CannEpil program through the pre-IND process and assigned an Investigational New Drug (IND) number, laying the foundation for future U.S. clinical development.
Jul 06, 2026 · 6 articles
Business
Australia: TGA Australia accreditation is one of the regulatory approvals held by the company, supporting its market access.
United States — Food and Drug Administration: The USFDA accreditation is a key regulatory approval for the company, enabling access to the US market.
Aug 03, 2026 · 6 articles
Business
Australia: Market where RECELL has TGA certification; no direct impact from this event.
United States — Food and Drug Administration: Regulator that approved RECELL; mentioned as part of company background, no new regulatory action.
Aug 09, 2026 · 6 articles
Domestic
Australia: Also cited as a model, but administers MMR in combination, contradicting the split recommendation.
United States — Food and Drug Administration: Responsible for approving any new separate vaccines, a process that could take years. It faces pressure to review unbundled shots without precedent.
Aug 10, 2026 · 235 articles
International
Australia: Australia is the home country of Orthocell and several corporate donors supporting the humanitarian effort.
United States — Food and Drug Administration: The United States — Food and Drug Administration cleared Remplir for use in April 2025, which is a significant regulatory milestone for the device.
Jun 29, 2026 · 6 articles
Business
Australia: Australia is included in the licensing agreement for vamorolone, potentially expanding patient access to the DMD treatment.
United States — Food and Drug Administration: The Taiwan FDA granted marketing approval for QUVIVIQ, a regulatory milestone that enables commercialization in Taiwan.
Aug 07, 2026 · 6 articles
Accidents
Australia: Australia>>> is one of multiple nations that have implemented travel restrictions in response to the Ebola outbreak, indicating a global concern.
United States — Food and Drug Administration: The United States — Food and Drug Administration has approved Inmazeb, a combination of antibodies, to treat Zaire Ebolavirus infection, which Regeneron Pharmaceuticals has donated for potential use in the current outbreak.
May 18, 2026 · 505 articles
Tech
Australia: Imlifidase is approved in Australia, expanding its global reach.
United States — Food and Drug Administration: The United States — Food and Drug Administration accepted the Biologics License Application for imlifidase, setting a PDUFA action date for December 19, 2026.
May 25, 2026 · 6 articles
Tech
Australia: Australia provided real-world registry data for one of the indirect treatment comparison studies, where vorinostat is part of the standard of care.
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) is mentioned as an entity to which suspected adverse reactions to POTELIGEO can be reported.
Jun 30, 2026 · 6 articles
Business
Australia: Australia is one of the markets where Menarini Asia-Pacific will commercialise Cosela, potentially improving patient access.
United States — Food and Drug Administration: The FDA approved Cosela, which is the basis for its use; the partnership does not directly affect the FDA.
Jul 21, 2026 · 8 articles
Business
Australia: Australia is one of the territories where Norgine has commercialization rights for PEDMARQSI. No direct impact from this event.
United States — Food and Drug Administration: The FDA approved PEDMARK in September 2022, which is a key regulatory milestone for Fennec. This event does not involve new FDA actions.
Aug 05, 2026 · 6 articles
Tech
Australia: An Australian cohort was part of a comparative-effectiveness study for Mogamulizumab, contributing to the real-world data.
United States — Food and Drug Administration: The United States — Food and Drug Administration is mentioned as the authority to report adverse reactions to POTELIGEO, indicating its regulatory role.
Jun 10, 2026 · 10 articles
Business
Australia: Australia is mentioned as one of the countries with which India has previously implemented a trade pact under the Modi government.
United States — Food and Drug Administration: Indian generic medicines approved by the United States — Food and Drug Administration>>> will receive fast-track marketing authorization in Oman>>> under the CEPA.
May 29, 2026 · 79 articles
Business
Australia: Australia previously approved WYNZORA, but is not directly affected by the Canadian launch.
United States — Food and Drug Administration: The FDA approved WYNZORA in the US in 2020, but is not directly involved in the Canadian launch.
Aug 20, 2026 · 6 articles
Business
Australia: Profound Medical's products are cleared in Australia.
United States — Food and Drug Administration: FDA has cleared TULSA-PRO and approved Sonalleve in the US.
Jul 16, 2026 · 7 articles
Business
Australia: Australia is a market where Norgine commercializes PEDMARQSI.
United States — Food and Drug Administration: The United States — Food and Drug Administration approved PEDMARK, a key product of Fennec Pharmaceuticals, which provides background on the company's operational success.
May 18, 2026 · 7 articles
Business
Australia: Australia is the home country of Telix, where the company is headquartered. The event is routine and does not affect the country.
United States — Food and Drug Administration: The United States — Food and Drug Administration is mentioned as the approver of Gozellix, a product in Telix's portfolio. The event is routine and does not affect the FDA.
Jul 30, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Australia and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard